Olema Oncology, Inc Investor Event Transcript, Nov 18, 2026
Olema Oncology, Inc. (OLMA)
The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints. AI summary
Conference Transcript - OLMA 2026-11-18
Dennis, Analyst — Spiegel
I have the wonderful pleasure of having the CEO of Olima Oncology now with us, Sean Bowen. Welcome. Thank you very much, Dennis, and thank you for acknowledging the change of our name. I saw. We pay attention. I like that. Perfect. So before we kind of dig into some of the data, maybe just remind us about, you know, Olima in general and some of the progress you guys have made in 2026.
Sean Bohen, CEO
Yeah, great. So Olima Oncology is a breast cancer-focused company, particularly focused on the vast majority of breast cancer, which is ER-positive, HER2-negative breast cancer. And we have two clinical stage assets. The lead is palizestrant. It targets the estrogen receptor, which is a primary driver of the growth and proliferation of these tumors. It's a complete estrogen receptor antagonist. It has a long half-life, 14 days. It has very high exposure to engage and turn off the receptor completely, and it has really unique combinability with other targeted agents. Two phase three trials. OPERO1 is a monotherapy trial in the second, third-line setting, and that reads out in Q1. The second is OPERO2, which is a first-line trial in combination with Kiskali. It's enrolling very well. We'll read out later. And then our other asset is a CAT6 inhibitor called OP3136, which is being studied in breast cancer in combination with fulvestrin and with palovestrin, our lead asset. And then we have kind of uniquely seen monotherapy activity with that molecule in castration-resistant prostate cancer. So the studies of that with Nubeca, the androgen receptor inhibitor, are just getting underway.
Dennis, Analyst — Spiegel
Perfect. Certainly a lot going on, but maybe we can just focus on OPERO-01, because that is going to be a fairly near-term readout in Q1. It's a phase three study. So, um, Obviously, investors, they've seen all these other, you know, oral SIRS and molecules that, you know, had a successful study in the mutant setting, the ESRO mutant setting, but not the wild type setting. So what gives you the confidence that pallid zesterner is the right molecule to really tease out that signal there?
Sean Bohen, CEO
Yeah, so the history here is The second third-line setting is patients who've progressed on a CDK4-6 plus an aromatase inhibitor. The most common resistance mutation that arises is an activating mutation of the ESR1 gene, which encodes the estrogen receptor. So what that does is it takes the estrogen receptor and turns it from a ligand-regulated transcription factor into a constitutively active transcription factor that doesn't need estrogen anymore, and that bypasses the aromatase inhibitor. That's about 40, 50 percent of patients. The remainder of the patients, they obviously progress, but they don't have this mutation, so it must be elsewhere that they're developing resistance. We know, because if you give targeted agents, you have to combine with an endocrine agent that the estrogen receptor is still active, but to date, they've been able to show some activity, about two months extension of PFS in the ESR1 mutant subset, but everyone has failed. In the wild type. And probably the biggest thing that gives us a hope that we could break that streak is our phase two data. So in our phase two study, we saw about 7.3 months median PFS in the ESR1 mutant, 5.5 months in the ESR1 wild type. That's the range that others saw in mutant. Actually, so if we, this is the classic oncology development question, does the phase 3 trial recapitulate the phase 2 result? And that's really what we're studying in OPERA 01. I'll only add that OPERA 01 is unique in its study design in that it is the only trial in this space that is specifically designed. To assess these two patient populations as individual endpoints, so ESR1, PFS and ESR1 mutant, and PFS and ESR1 wild type.
Dennis, Analyst — Spiegel
Okay. As it relates to PFS, what is clinically meaningful in the ESR1 mutant and wild type population?
Sean Bohen, CEO
Yeah, so clinically meaningful in the mutant is pretty clearly, you know. Two months or almost two months. That's what's been shown by others. So by two months, I mean two months prolongation of PFS from that shown with fulvestrin or eczema stain. So in most cases, that's about two or three months, so you go to four or five months with the next generation drugs. The other thing that happens there is you avoid the large-volume intramuscular injections of fulvestrin. You get to go to oral pill formulation. So that two months is obviously significant. It would be somewhat efficacy-wise undifferentiated. So the differentiation opportunity is to have better efficacy in that mutant population. As I mentioned, 7.3 months is what we saw in the Phase 2 setting. In the, there's nothing that's worked in ESR1 wild type. So the feedback we get from breast cancer doctors, from our investigators, steering committee members, is, you know, they want to see something. They want to see some activity there. So it may not be quite two months, but I think, you know, we have to get enough to be statistically significant.
Dennis, Analyst — Spiegel
If it is, you know, in the wild type, if it is below two months, are you guys still powered enough to detect that?
Sean Bohen, CEO
We believe so. So the way we powered the trial was we powered... The trial, so that a minimally, clinically meaningful benefit would be statistically positive. And so the one other attribute that we have is There are actually more patients on the trial that are ESR-1 wild type than are ESR-1 mutant. So that in and of itself contributes to a little bit more power to detect a smaller difference in that wild type subset.
Dennis, Analyst — Spiegel
Understood. Okay. When you talk with doctors, and I'm, you know, aware of multiple oral service that are approved in the ESR-1 mutant setting, And to your point, some are like 1.9 months, some are 1.7 months. I mean, Lily is 1.7 and is doing $300 million run rates. Right now.
Sean Bohen, CEO
Yeah, that's right.
Dennis, Analyst — Spiegel
So I guess when you talk with doctors, you know, what would... Be considered clinically differentiated versus what's out there. Meaning, if you guys have three months PFS Delta, is that amazing or does it need to be higher? Just help us give a little bit of feedback from doctors.
Sean Bohen, CEO
Right. So it's really interesting when you have these kinds of conversations because usually what happens is you ask them, well, what would you like to see? And they kind of go optimistic. They go a little bit... We'd really like to see something meaningful. So if you ask them, they'll say, well, now we have two months, we'd like to see four. And then usually what we'll do is we'll say, yeah, right, that'd be great. What if we got three? Oh, yeah, no, that'd be good. Two. So I think they want to see something that they feel. It's different. I think that if we were four months rather than two, it would be, I think, for the vast majority, very clear. But I do think there is probably some room to feel differentiated with less than the additional two months. The other thing is, remember, you know, it is oncology. So to your point, that there are other differentiators. We don't cause diarrhea. Imlunestrin causes diarrhea. But efficacy really drives behavior in oncology.
Dennis, Analyst — Spiegel
Yeah. And then in phase two, you guys have 7.3 months, I believe.
Sean Bohen, CEO
That's right. And that was in the mutant setting, right. So that's where we would be trying to differentiate.
Dennis, Analyst — Spiegel
So then remind us the range of where control would be.
Sean Bohen, CEO
We think it's going to be two to three months. So these are patients who have – our trial design is very, very much like the Emerald trial, the trial that led to ORSERDU's approval. So everybody has progressed on a CDK4-6 plus an AI in their first-line setting. That's really the definition of second line. And then we do also allow them to have had another prior endocrine therapy. That's why the control arm is fulvestrant or exomestane. If they've had fulvestrant, they won't get it again, but they could go to exomestane. And then the other arm is obviously palazestrant as a monotherapy. So we think we'll be two to three months. There are a couple things we did that are different from our phase two and from Emerald. We excluded prior chemotherapy in the advanced setting. We also required that whatever prior was the last prior regimen, that patients were able to stay on it for six months without progression.
Dennis, Analyst — Spiegel
Mm-hmm. Essentially establishing that they're endocrine-sensitive.
Sean Bohen, CEO
Yeah, or trying to at least somewhat select against true endocrine resistance, right? Yeah, so it's more a little bit of a negative enrichment away from the endocrine-resistant population. We do believe that eventually in the – so the treatment objective in this line of therapy is to push back chemotherapy as long as possible. We do believe that eventually, at some point, they develop true endocrine resistance. In other words, they mutate enough other pathways that they're actually bypassing the use of the estrogen receptor.
Dennis, Analyst — Spiegel
Yeah, okay. When you look at Lilly and just some of their commercial, you know, quote-unquote success currently with only a 1.7-month BFS, Delta, like, what does that tell you about the market? Is it just because Lilly is such a huge organization, or, you know, what's been the doctor feedback around, you know, around that product that's really driving sales?
Sean Bohen, CEO
Yeah, so the first thing is I don't think we should. It would be foolish to underestimate the commercial power of Lilly. I think that is certainly a component of it. But I will say that if you look at, or SIRDU, Minerini is not a public company, Stemline is not public, but you can kind of backwards infer some of what's going on there, either by prescription information. Or also, there are organizations that get paid royalties from Orsardu that report what those royalty rates are. And we do think that $600 million to $800 million a year is probably where Orsardu is right now. So this is a very large market. I think it speaks to the unmet need. I do think there's one other differentiator that Imlunestrant has, which is that they do also have a label in combination with Abemacyclib. So if you want to give a combination. In that ESR1 mutant setting, then they have that as a possibility. But I think really it speaks to the continued unmet in this population. Patients want another treatment alternative. They want to avoid chemotherapy, and they don't want injections. They want to be able to take an oral medication and have a more normal life.
Dennis, Analyst — Spiegel
Yeah, I think one of the, you know, investor questions that That we get is that, you know, the ESR1 immune landscape is fairly crowded, right? And, uh... You know, I guess, what is your view on that, given what we've seen with Lilly, given what we've seen with Orsardu? Do you think there's room for another player? You know, and this is all assuming that you guys have similar PFS. It would be different if you have, like, three months or four months, but I'm just curious, what do you think about some of those arguments?
Sean Bohen, CEO
It's a $2 billion market, right? So even capturing a significant minority of that market is meaningful for a company with a $700 million market cap. The other thing is you have to realize that one of the important aspects of... Launching palisestrine. Assuming that the Opera 01 readout enables filing and launch is some of the value of it is setting up the market for the second readout, the Opera 02 readout with Kiskali in the first-line setting, which is a $10 billion-plus market. And remember, the only next-generation endocrine agent, the only CRAN that is currently being studied in that. The line of therapy is palizestrin.
Dennis, Analyst — Spiegel
So, maybe that's a great segue to talk a little bit more about first line, and, you know, obviously Persevera read out this year, Serena IV read out this year, and both were negative, though Persevera had a pretty clinically meaningful, I think, delta on PFS, but, like, what are some of the learnings from those studies? What are you going to look for at San Antonio in a couple of weeks, you know, when we get This arena for top line.
Sean Bohen, CEO
Right. Yeah, so we've had two readouts this year. Um, uh, Persevera, which was gerodestrant, um, Roche's, um, uh, SIRD molecule in combination with Ibrant's palbociclip. It did not meet its primary endpoint. It missed it very narrowly for hazard ratio, but there's very clear evidence of activity of doing better than the AI. As you said, the point estimate of PFS was five months. If the hazard ratio had hit, that would be approvable. That would change practice. This is, there were some trial design. Unique aspects that I think didn't help them. Primarily, they enrolled endocrine-resistant patients. So they enrolled patients who had prior adjuvant therapy but progressed within one year of discontinuing it. The standard of care is not to continue to give them. Aromidase inhibitors to switch their therapy. But that is not what's done in that subset. That subset did poorly. I guess lesson learned, the lesson would be don't include those patients. Actually, no one does other than that trial. So OPERO2 doesn't have them. So we didn't have to change anything. But I think it did teach us something that that is an important criterion. On the other hand, I think the signal that they did see is very positive. If they had seen no signal at all, I think we'd be wondering, can you improve upon the AI? They just narrowly missed, and I think with a better agent, a better combination, it really is quite encouraging for the outcome of OPERO2. The Serena 4, as you said, we haven't seen the data yet. So we do... We view camazestrin as sort of the weakest of this class because its dose, its exposure is so low. Its exposure is so low because it has toxicities, cardiovascular and ocular toxicities, that they can't dose above 75 milligrams. So they indicated in their press release, we think we'll see some separation of the curves because they indicated a superiority. I wouldn't be surprised if it's not as compelling as Persevera. Now, there are some other things, though. One, they did not put in the endocrine-resistant patients that were in Persevera. We are really interested in the control arm because one thing that's common in oncology is a given drug or combination of drugs often performs better over time. Oncologists are very good at managing toxicity. And when they do that, they maintain dose intensity, they have fewer discontinuations, and the drug does better. Some of the data we use to plan OPERA-02, particularly to predict the control arm outcome, is pretty old. So Serena 4 gives us a much more modern estimate of the performance of CDK4-6 plus AI in the first-line setting, and in a population that is very, very similar to OPERA-02. So we'll take a look at that when we see it in December, and then what we'll do is we'll see if we have to use, if we should really be using different assumptions in our statistical plan, and then really the variable we might change is enrolling more patients. The trial's enrolling very quickly, so I don't think we would take much of a timeline hit if we were to decide that we needed to expand the trial a bit.
Dennis, Analyst — Spiegel
Okay. I feel like in the first line, there's a lot of moving parts, right? Because Persevera, I feel like, you know, not as endocrine sensitive, but you do have a more potent molecule. For serenophore, it's more endocrine sensitive, but less potent. But I feel like for you guys in upper O2, you guys are more potent, you get full exposure, and you guys are enrolling endocrine sensitive patients. So I feel like the POS should be a little bit higher than where the stock is currently trading.
Sean Bohen, CEO
Well, yeah. I think we're undervalued for CAT6, so I think your point's a good one.
Dennis, Analyst — Spiegel
Okay. So then I guess sticking with San Antonio and some other updates, I mean, you guys will be having, you know, disclosing some CAT6 data, some combo data, as well as some, you know, some palazestrin combo data. Yes, that's right. So just remind us, what should we expect at San Antonio? And then also within the abstracts, I think that'll be released next week.
Sean Bohen, CEO
Yeah, yeah, so that, so that, the, the. The abstract for the Everolimus combo has some stuff in it that's a much more mature data set. So the Everolimus combo with palizestrin is a poster. This is a relatively mature phase two data set of post-CDK4-6 with Everolimus. One of the differentiators for palizestrin that we think is very important is we have unique combinability. We have combined at full doses of palisestrin with full dose, palbociclib, ribociclib, alpalisib, everolimus, atormaciclib, which is the Pfizer CDK4 selective molecule, and RCAT6 inhibitor, OP3136. That's ongoing. So everolimus is just another combination data set to show our combinability. I think the efficacy, you will see Kaplan-Meier curves. You'll see them split out by wild type and mutant. I think that will be interesting for people. The tolerability with the dose will obviously be interesting. Yeah, so I think that one is interesting.
Dennis, Analyst — Spiegel
Should people be looking at the Avera study?
Sean Bohen, CEO
That's probably the one that's closest to be able to do comparison to. These patients are a bit more heavily pretreated. Avera is pretty much pure second line, so our patients are more heavily pretreated than that. But I think that's probably what people will compare to recognizing the limitations across trial comparison. The other, we have a oral presentation, which is the tyrmocyclic combination data. A lot of the tolerability profile of the combination, some early efficacy data. It's not mature yet. Half the patients are actually first-line patients, so that will take a while. Those patients do quite well. And then the other poster presentation, a late-breaking abstract poster, is our first combination data with OP3136, which is our CAT6 inhibitor. So we presented the first monotherapy data. At ASCO, this is an update on the breast cancer patients and monotherapy. There will be more follow-up, more patients. And then our first filvestrant combination data. So, again, tolerability, early efficacy at multiple dose levels. As I said, the palazestrant combination is ongoing. That's a novel novel, so it's a little bit behind that data. We think we'll be around mid-year next year. Pre-clinically, the palazestrant combo looks very, very interesting. It looks like palazestrant very much potentiates the activity of CAT6. Abstracts for those two posters don't say a whole lot. They were written a while ago, but I think the posters themselves will be illuminating.
Dennis, Analyst — Spiegel
If you take a step back, going into some of these updates, what is sort of your messaging around each of these data sets outside of? It'll look interesting.
Sean Bohen, CEO
Unique combinability, and I think you're going to see that there. I think in the context of the CAT6 inhibitor, look at tolerability. Pfizer's molecule certainly demonstrates this is a validated target in the breast cancer setting. They do, at their Phase III dose, have 50-50% dose reductions or discontinuations in Phase II, primarily due to cytopenia, to myelosuppression. So I think it'll be interesting for people to be able to see that. There's early efficacy in a more heavily pretreated group, again. Yeah, a tormaciclib is, again, an everolimus is this concept of unique combinability of palizestrin. That's important because... While endocrine therapy is given as monotherapy, sometimes doctors and patients want to combine it with another targeted agent. That isn't always easy to do, either due to classical drug-drug interactions or enhancement of toxicity. And so that's one of the reasons we're generating all these data sets on combination.
Dennis, Analyst — Spiegel
Okay. Yeah, I feel like that's actually really interesting for Olimo, And I think it's something that investors aren't necessarily appreciating. Because you have two novel compounds, they're combinable, but you're also combining with many of these other mechanisms that in three to five or ten years is going to become standard of care. And I think that's something that I think investors should start thinking about.
Sean Bohen, CEO
Yeah, I think that's right. The one other thing about CAT6, obviously, that ASCO will not be at the San Antonio Breast Cancer Symposium, is that we saw single-agent activity in castration-resistant prostate cancer uniquely. And so the combination with Nubeca, the androgen receptor inhibitor from Bayer, will start very soon. Data for that one, you know, fluence will probably be end of year next year, but we'll keep following it.
Dennis, Analyst — Spiegel
Got it. Okay. Maybe in the last minute or two, we can talk a little bit about adjuvant. You know, how much of a priority is it for you to go into that? I appreciate that funding. You know, it's going to be an incredibly expensive trial. Yeah. That is clearly where, you know, where the puck is going. And then you just saw Roche, right, like their data, they're going to make a pretty big presence in the adjuvant as well. Yeah. So I'm just curious how you're thinking about that opportunity and, like, what is the best way to capitalize on that?
Sean Bohen, CEO
Yeah, I mean, I think you're absolutely right about it. The Ladera data for gerodestrant really demonstrated that these next-generation agents have activity in the ESR1 wild-type endocrine-sensitive population, and I do think it'll be a big indication for them. They have said that. Absolutely right. It looks like they should be approved by the end of the month, and I certainly would be very surprised if that doesn't occur. Um, it's a little complicated because CDK4-6 is used in most of those patients now, and that wasn't in the LADERA trial, so I think... Oncologists are struggling with how we get this, but I think it is also true that the data that it's better than AI is compelling. So, um... I think a different trial would be the one to do in the future. It is large. It is expensive. You know, our plan with assuming OPERA 01 is positive is to seek a collaborator because we will file and launch in the United States. We can file outside the U.S., but we do not intend to launch and promote, so we'd need a collaborator to do that. I think maximizing the value of PALS esterant means an adjuvant opportunity, and that will be part of those discussions.
Dennis, Analyst — Spiegel
Perfect. Well, I think we are out of time, but it's great to see you. Thank you. And thanks for hanging out with me.
Sean Bohen, CEO
Yeah. Thank you, Dennis. Thanks. Thank you.